WEST BRIDGEWATER, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) today announced that EdgeWater Research Partners LLC ("EdgeWater") has initiated research coverage on the Company. Copies of this research report can be obtained by contacting Mr. David Lavigne at EdgeWater Research Partners, 1946 Mountain Maple Ave., Highlands Ranch, CO, 80129 by telephone (303-593-2877) or email (dave@edgewaterresearch.com), or by contacting EdgeWater directly through their website (http://www.edgewaterresearch.com).
Any opinions, judgments, estimates, or forecasts regarding the Company's historical or predicted performance or operations made by EdgeWater are theirs alone and do not represent opinions, judgments, estimates, or forecasts of the Company or its management. The Company does not by its reference to the research prepared by EdgeWater imply its endorsement or adoption of or concurrence with such information, conclusions, or recommendations. In August 2005, the Company paid a fee of $8,000 to attend EdgeWater's fall 2005 Micro/Small Cap Conference for Investment Professionals.
About Pressure BioSciences, Inc.
Following the sale of substantially all the assets and selected liabilities of its BBI Diagnostics and BBI Biotech Divisions to SeraCare Life Sciences, Inc. on September 14, 2004, Boston Biomedica, Inc. changed its name to Pressure BioSciences, Inc (PBI). PBI is a publicly traded, early-stage company focused on the development of a novel technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio- molecular interactions. PBI currently holds 13 US and 4 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics, and protein purification. PBI owns a 30% passive investment in Source Scientific, LLC, an instrumentation company that develops and manufactures PBI's PCT equipment, as well as a passive investment in Panacos Pharmaceuticals, Inc., an antiviral drug discovery and development company.
Visit us at our website http://www.pressurebiosciences.com
Investor Contacts:
Richard T. Schumacher, President & CEO Pressure BioSciences, Inc.
R. Wayne Fritzsche, Chairman (508) 580-1818 (T)
SOURCE Pressure BioSciences, Inc.
-0- 10/18/2005
/CONTACT: Richard T. Schumacher, President & CEO, or R. Wayne Fritzsche,
Chairman, both of Pressure BioSciences, Inc., +1-508-580-1818/
/Web site: http://www.pressurebiosciences.com
http://www.edgewaterresearch.com /
(PBIO)
CO: Pressure BioSciences, Inc.; EdgeWater Research Partners LLC
ST: Massachusetts, Colorado
IN: BIO HEA MTC
SU: SVY
AC-CP
-- NETU026 --
5932 10/18/2005 11:30 EDT http://www.prnewswire.com